Actelion has announced it is acquiring biopharmaceutical company
CoTherix for $420m (€328m) with the objective of taking over and
increasing the distribution of Ventavis, the only approved inhaled
therapy for the treatment of Pulmonary...
Swiss drugs firm Novartis are claiming success in its latest
treatment for hypertension. Aliskiren - the first in a new class of
antihypertensive drugs has shown to be effective as a single
treatment for patients with high blood pressure.
A study showing that drugs distributed in blister packages rather
than in bottles increase the likelihood that medications will be
taken properly, could help encourage the take-up of unit-dose
packaging in the US market, reports Phil...
German pharmaceutical company, Boehringer Ingelheim (BI) and Ark
Therapeutics have signed an agreement granting BI exclusive rights
to Ark's intellectual property in relation to BI therapies
affecting the renin-angiotensin system.
Swiss drugmaker Novartis says that its renin inhibitor drug
aliskiren (SPP100), which potentially represents the first in a new
class of orally-active drugs for high blood pressure, has shown
promising data in a clinical trial.
Speedel Experimenta has announced the completion of its human
micro-dosing studies into renin inhibitors that are set to provide
an effective means of treating hypertension and for protecting end
organs such as the heart and kidneys.